Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.
Enesi Pharma (“Enesi”) announces that ImplaVax® has won the ‘Best New Vaccine Technology/Platform Award’ at the World Vaccine Congress Washington Virtual annual event (28 September – 1 October 2020). The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.
Enesi Pharma is delighted to announce the appointment of Dr Keith Howard as Chief Scientific Officer. Dr Howard is a seasoned vaccine development expert who will lead Enesi’s R&D efforts to develop novel solid-dose vaccines for needle-free delivery for both in-house and partnered programmes, progressing them into clinical development.
The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.
The UK Government grant will support new and existing projects until March 2022. Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for routine adoption of advanced therapies.
- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment
- Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills
- New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
Supporting the race for treatments new collaboration launched to drive understanding of COVID-19
Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.